Profiling protéique SELDI-TOF et cancer du sein - Applications cliniques potentielles

Anthony Gonçalves; François Bertucci; Daniel Birnbaum; Jean-Paul Borg

doi:10.1051/medsci/2007231s23

Accueil

Tous les numéros

Volume 23 (Mars 2007) Hors série n° 1

Med Sci (Paris), 23 (2007) 23-26

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 23, Mars 2007 Protéomique clinique en oncologie


Page(s)		23 - 26
Section		M/S revues
DOI		https://doi.org/10.1051/medsci/2007231s23
Publié en ligne		15 mars 2007

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 : 747–52. [Google Scholar]
Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006; 5 : 1772–86. [Google Scholar]
Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292 : 587–92. [Google Scholar]
Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 : 572–7. [Google Scholar]
Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100 : 12343–8. [Google Scholar]
Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64 : 5882–90. [Google Scholar]
Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96 : 353–6. [Google Scholar]
Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4 :309–14. [Google Scholar]
Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48 : 1296–304. [Google Scholar]
Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4 :203–9. [Google Scholar]
Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005; 14 : 250–5. [Google Scholar]
Becker S, Cazares LH, Watson P. Surfaced-enhanced laser desorption/ ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004; 11 : 907–14. [Google Scholar]
Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17 : 301–7. [Google Scholar]
Coombes KR, Fritsche HA Jr, Clarke C, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49 : 1615–23. [Google Scholar]
Sauter ER, Shan S, Hewett JE, et al. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005; 114 : 791–6. [Google Scholar]
Goncalves A, Esterni B, Bertucci F, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006; 25 : 981–9. [Google Scholar]
Ricolleau G, Charbonnel C, Lode L, et al. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 2006; 6 : 1963–75. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 : 747–52. [Google Scholar]

[2] Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006; 5 : 1772–86. [Google Scholar]

[3] Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292 : 587–92. [Google Scholar]

[4] Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 : 572–7. [Google Scholar]

[5] Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100 : 12343–8. [Google Scholar]

[6] Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64 : 5882–90. [Google Scholar]

[7] Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96 : 353–6. [Google Scholar]

[8] Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4 :309–14. [Google Scholar]

[9] Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48 : 1296–304. [Google Scholar]

[10] Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4 :203–9. [Google Scholar]

[11] Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005; 14 : 250–5. [Google Scholar]

[12] Becker S, Cazares LH, Watson P. Surfaced-enhanced laser desorption/ ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004; 11 : 907–14. [Google Scholar]

[13] Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17 : 301–7. [Google Scholar]

[14] Coombes KR, Fritsche HA Jr, Clarke C, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49 : 1615–23. [Google Scholar]

[15] Sauter ER, Shan S, Hewett JE, et al. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005; 114 : 791–6. [Google Scholar]

[16] Goncalves A, Esterni B, Bertucci F, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006; 25 : 981–9. [Google Scholar]

[17] Ricolleau G, Charbonnel C, Lode L, et al. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 2006; 6 : 1963–75. [Google Scholar]